Skip to main
DFTX

DFTX Stock Forecast & Price Target

DFTX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Definium Therapeutics is developing a promising range of innovative therapies aimed at addressing the underlying causes of psychiatric and neurological disorders. With four Phase 3 trials in progress for their lead candidate DT120 ODT, the company has received FDA Breakthrough Therapy Designation for generalized anxiety disorder (GAD) and is on track for late 2Q26 and early 3Q26 results in MDD and GAD, respectively. Additionally, their Phase III trial in post-traumatic stress disorder (PTSD) is set to begin next year, indicating a robust pipeline of potential treatments. With a strong body of data and positive psychiatric feedback, there is significant upside potential for Definium's lead drug in the treatment of various mental health disorders.

Bears say

Definium Therapeutics is a pharmaceutical company with a focus on developing therapeutics for psychiatric and neurological disorders. While its innovative approach towards addressing underlying causes and long-term remission in these disorders is promising, there are several key risks that could limit the success of the company. These include potential setbacks in efficacy and safety, concerns about the long-term effects of its compounds, and challenges in obtaining regulatory approvals and market acceptance. Until there is more data available from the ongoing clinical trials, there is significant uncertainty surrounding Definium Therapeutics and its ability to capitalize on its potential benefits.

DFTX has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Definium Therapeutics Inc (DFTX) Forecast

Analysts have given DFTX a Buy based on their latest research and market trends.

According to 8 analysts, DFTX has a Buy consensus rating as of Jun 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Definium Therapeutics Inc (DFTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.